 SAN DIEGO, April 12, 2021 GLOBE NEWSWIRE -- Oncternal Therapeutics, Inc. Nasdaq: ONCT, a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Chase Leavitt as General Counsel. Mr. Leavitt joins the Company with extensive experience providing strategic, transactional, financial, and operational advice to life sciences companies. 